Disease · MONDO_0019037

progressive supranuclear palsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. progressive supranuclear palsy. Diseases, record MONDO_0019037. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019037

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: progressive supranuclear palsy; Open Targets
Open Targets ID: MONDO_0019037; Open Targets
Other names: PSP syndrome, Steele-Richardson-Olszewski disease, Steele-Richardson-Olszewski syndrome, progressive supranuclear ophthalmoplegia, progressive supranuclear ophthalmoplegia (disorder), supranuclear palsy, progressive; Open Targets
Disease Ontology: DOID:678; Disease Ontology
MeSH: D013494; MeSH
NCI Thesaurus: C85028; NCI Thesaurus
Orphanet: ORPHA:683; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 22 drugs, from ClinicalTrials.gov; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RASAGILINE	CHEMBL887	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RILUZOLE	CHEMBL744	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RIVASTIGMINE	CHEMBL636	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DAVUNETIDE	CHEMBL2103826	Protein	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
UBIDECARENONE	CHEMBL454801	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
SODIUM PHENYLBUTYRATE	CHEMBL1746	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
TILAVONEMAB	CHEMBL4297860	Antibody	Phase 2	ClinicalTrials.gov and TTD	6	4	4	Drugs and targets
GOSURANEMAB	CHEMBL3990042	Antibody	Phase 2	ClinicalTrials.gov and TTD	5	3	3	Drugs and targets
TERTOMOTIDE	CHEMBL2108308	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MAPT	Microtubule-associated protein tau	3	Microtubule-associated protein tau inhibitor	Phase 2	https://conductscience.org/library/genes/4137	Drugs and targets
ACHE	Acetylcholinesterase	2	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/43	Drugs and targets
GSK3B	Glycogen synthase kinase-3	2	Glycogen synthase kinase-3 beta inhibitor; Glycogen synthase kinase-3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2932	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/7915	Drugs and targets
BCHE	Cholinesterases; ACHE & BCHE	1	Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/590	Drugs and targets
DRD2	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Unknown	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Unknown	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Unknown	https://conductscience.org/library/genes/1815	Drugs and targets
GSK3A	Glycogen synthase kinase-3	1	Glycogen synthase kinase-3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2931	Drugs and targets
IMPA1	Inositol monophosphatase 1	1	Inositol-1(or 4)-monophosphatase 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3612	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03068468	Study of BIIB092 in Participants With Progressive Supranuclear Palsy	Phase 2	490	2020-12-21	Supranuclear Palsy, Progressive	GOSURANEMAB	Its record names the disease	ClinicalTrials.gov
NCT02985879	A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)	Phase 2	378	2021-02-03	Progressive Supranuclear Palsy	TILAVONEMAB	Its record names the disease	ClinicalTrials.gov
NCT03391765	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	Phase 2	142	2021-02-03	Progressive Supranuclear Palsy (PSP)	TILAVONEMAB	Its record names the disease	ClinicalTrials.gov
NCT05819658	GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)	Phase 2	78	2026-02-10	Progressive Supranuclear Palsy	TERTOMOTIDE	Its record names the disease	ClinicalTrials.gov
NCT00703677	A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration	Phase 1/2	17	2010-06-11	Progressive Supranuclear Palsy, Corticobasal Degeneration	LITHIUM CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT01537549	Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy	Phase 1/2	11	2017-04-12	Progressive Supranuclear Palsy	LIPOIC ACID, ALPHA	Its record names the disease	ClinicalTrials.gov
NCT00211224	Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)	Phase 3	800		Multiple System Atrophy, Progressive Supranuclear Palsy	RILUZOLE	Its record names the disease	ClinicalTrials.gov
NCT01110720	Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy	Phase 2/3	313		Progressive Supranuclear Palsy	DAVUNETIDE	Its record names the disease	ClinicalTrials.gov
NCT01049399	Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy	Not applicable	146		Progressive Supranuclear Palsy	TIDEGLUSIB	Its record names the disease	ClinicalTrials.gov
NCT02839642	Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy	Phase 3	106		Progressive Supranuclear Palsy (PSP)	RIVASTIGMINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
BIIB092 2000 mg (PC Period) vs Placebo (PC Period): Number of Participants With Treatment Emergent Antibodies (Anti-BIIB092) Positive Results in Serum	0 of 323	7 of 160	483	NCT03068468

Source Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27136096	RESULT	1	PubMed
38825840	DERIVED	3	PubMed
34736158	DERIVED	1	PubMed
34385707	DERIVED	1	PubMed
33609476	DERIVED	1	PubMed
31122495	DERIVED	1	PubMed
28436538	DERIVED	2	PubMed
24873720	DERIVED	1	PubMed
21829612	DERIVED	1	PubMed
21386111	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019037

GET https://conductscience.org/api/diseases/v1/MONDO_0019037/drugs?page=2

API reference For AI assistants